The 4th Human Abuse Liability & Abuse-Deterrent Formulations conference will be the largest and most specifically focused event in the world devoted entirely to designing, testing and marketing prescription drugs with a lowered risk of abuse. If you are interested in sponsorship or exhibition opportunities, please contact Eric Morrin, Senior Business Development Manager, at 212-400-6228 or email@example.com.
Alcami is a world-class supplier of comprehensive pharmaceutical development and manufacturing services headquartered in Wilmington, NC. We provide flexible, transparent and innovative services to small and mid-size pharma and biotech companies by offering individualized and integrated services across Active Pharmaceutical Ingredients (APIs), Drug Product, Development Services, and Analytical Testing. We strive to be the most customer-focused and reliable partner built on safety, compliance, strong scientific expertise and leading technologies.
DRUGSCAN©’s CAT.one™ laboratory-based manipulation and extraction studies are designed and conducted to produce data that can predict a product’s strengths and weaknesses to physical and chemical manipulations as well as support abuse-deterrent label claims. Employing state of the art technology and abuse-deterrent testing expertise, DRUGSCAN© has been at the forefront of designing and conducting manipulation and extraction studies for many of the leading abuse-deterrent product developers in the US and around the world.
Phlexglobal are the Trial Master File (TMF) experts, and pioneers in the provision of innovative, flexible and technology-enabled TMF solutions and services.
A specialist provider of electronic Trial Master File (eTMF) solutions and other support services to the global clinical research market, we offer a unique combination of technology, quality and services that deliver a range of flexible, targeted solutions to the life science industry.
The RADARS® System collects timely product- and geographically specific prescription drug abuse, misuse and diversion data utilizing a mosaic strategy across all phases of the drug abuse pathway and provides these data to the pharmaceutical industry, regulatory agencies, policymakers and medical/public health officials. Additional RADARS® System services include postmarket surveillance, epidemiological studies, publication strategy, advisory committee consultation and advisory board participation. The RADARS® System is a governmental nonprofit operation of Denver Health and Hospital Authority.
The Grünenthal Group: International, Successful, Innovative
The Grünenthal Group is an independent, research-based pharmaceutical company headquartered in Germany. Grünenthal is present in 32 countries with 5,300 employees worldwide. In 2014 revenues were approximately $1.25 billion. Since 2010, Grünenthal has marketed its proprietary abuse-deterrent technology INTAC®, which restricts manipulation and impedes abuse due to high mechanical stability.
Vince & Associates Clinical Research
Altasciences Clinical Research encompasses Algorithme Pharma and Vince & Associates Clinical Research, making it one of the largest early phase clinical CROs in North America. With more than 25 years of experience, Altasciences provides clinical development services to biopharmaceutical companies worldwide, including study conduct, medical writing, biostatistics, data management and bioanalysis.